Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 December 2019 | Story Charlene Stanley | Photo Anja Aucamp
Sprouting Hope
Shadei Lepholletse, BSc Genetics and Physiology; Masabata Sebusi, BCom Accounting; and Tumelo Zondi, BCom Entrepreneurial Management; three of the directors of Sprout Africa, an agriculture and agri-processing company - the perceived potential of which has earned them each a place on the list of News24’s 100 Young Mandelas of the Future.

Enactus, 100 Young Mandelas of the Future, Sprout Africa, Masabata Sebusi, Shadei Lepholletse, Tumelo Zondi, and Farai Mzungu

Kovsie students’ innovative agri-processing venture is paying off. Two years ago, a seed of resolve was planted in four young UFS women. They entered the Enactus National Competition for entrepreneurship projects –and came stone last.

But instead of giving up, they re-grouped, re-evaluated their priorities, and came up with an innovative agri-processing community-upliftment concept that has earned each of them a place on News24’s list of 100 Young Mandelas of the Future.

“We asked ourselves what the big businesses out there were looking for when it came to community development. At that stage, we focused on arts and crafts and recycling. But we realised the need was for projects providing solutions around food insecurity, water management, and sustainable development,” explains Masabata Sebusi, final-year BCom Accounting student.

Masabata and her three partners, Shadei Lepholletse, Tumelo Zondi, and Farai Mzungu, are all studying in different fields. They pooled their diverse insights, knowledge, and perspectives. And Sprout Africa was born.

The company’s aim is to give people in rural communities training in modern farming techniques, equipping them with basic business skills and helping them to find an outlet for their produce. As part of the process, the women approached potential business partners – from local supermarkets to big commercial companies – to negotiate on behalf of the farmers.

This time, they seem to have struck the right nerve. Having won various grants while the concept as still an Enactus project, they have since registered Sprout Africa as a company. Various stakeholders have already shown interest to partner with them.

Their main advice to fellow entrepreneurs: Think outside the box, find innovative ways to solve problems, learn from the communities you serve, and collaborate with people who have different skills from you.

Except for Farai, who graduated earlier this year, all of them are in their final year of study. Next year, they won’t be job hunting like other new graduates. They’ll simply be stepping full time into their innovative enterprise.

An enterprise that promises to keep on sprouting and growing. And hopefully produce seeds of inspiration for other students to pick up.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept